Description
Cerivastatin is an inhibitor of HMG-CoA reductase that exhibits anti-hyperlipidemic, anti-atherosclerotic, anti-fibrotic, and anti-inflammatory activities. Cerivastatin has been used clinically to lower cholesterol and treat cardiovascular disease, but has since been withdrawn from the market due to associations with the development of rhabdomyolysis. In vitro, cerivastatin decreases production and activation of IL-6, AP-1, and NF-κB. In hepatocytes, this compound decreases TNF-α-induced production of PAI-1, preventing atherosclerosis and fibrosis.
References
Takeshita Y, Takamura T, Hamaguchi E, et al. Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line. Metabolism. 2006 Nov;55(11):1464-72. PMID: 17046548.
Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005 Feb;19(1):117-25. PMID: 15660968.
Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J. 2004 Jun;147(6):956-65. PMID: 15199341.
Viedt C, Shen W, Fei J, et al. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9. Basic Res Cardiol. 2003 Nov;98(6):353-61. PMID: 14556080.
